Caligan Partners LP - 29 Jun 2023 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role
10%+ Owner
Signature
Caligan Partners LP, By: /s/ David Edward Johnson, Partner
Issuer symbol
LAB
Transactions as of
29 Jun 2023
Net transactions value
$0
Form type
4
Filing time
03 Jul 2023, 17:18:05 UTC
Previous filing
30 Dec 2022
Next filing
11 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock, $0.001 par value per share ("Common Stock") Other -108,879 -1.3% 8,467,920 29 Jun 2023 See footnote F1, F2
transaction LAB Common Stock Other -670,466 -7.9% 7,797,454 03 Jul 2023 See footnote F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the total number of shares of Common Stock beneficially owned by Caligan Partners LP ("Caligan") following the termination of an investment management agreement with respect to an account previously managed by Caligan.
F2 The securities reported herein are held by an affiliated fund of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.
F3 This transaction represents an in-kind distribution by certain funds and accounts to which Caligan serves as the investment manager.

Remarks:

The Reporting Persons disclaim beneficial ownership in the securities reported on this Form 4 except to the extent of his or its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that any of the Reporting Persons are the beneficial owner of such securities for purposes of Section 16 or for any other purpose.